| Date | Title | Description |
| 17.10.2018 | Term Sheet — Wednesday, October 17 | THREE THINGS
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
THE PATH TO IPO: The ride-hailing wars are starting to look like a game of chess. When Uber makes a move, Lyft is rea... |
| 16.10.2018 | Velicept Therapeutics Raises an Additional $15M In Series B | MALVERN, Pa.--(BUSINESS WIRE)--Velicept Therapeutics, a privately-held clinical stage pharmaceutical company dedicated to the development of best-in-class compounds for the treatment of urological and gastrointestinal disorders, announced t... |
| 16.10.2018 | Velicept Therapeutics Raises Additional $15M | Velicept Therapeutics, a Malvern, PA-based clinical stage pharmaceutical company focused on advancing compounds for the treatment of urological and gastrointestinal disorders, closed on the expansion of a Series B financing raising an addit... |
| 16.10.2018 | Velicept Therapeutics Raises an Additional $15 Million in Series B Round, | MALVERN, Pa.--(BUSINESS WIRE)--Velicept Therapeutics, a privately-held clinical stage pharmaceutical company dedicated to the development of best-in-class compounds for the treatment of urological and gastrointestinal disorders, announced t... |
| 16.10.2018 | Velicept Therapeutics Inks $15M Series B |
MALVERN, PA, Velicept Therapeutics, a clinical stage pharmaceutical company focused on treating urological and gastrointestinal disorders, has raised $15 million in funding.
>> Click here for more funding data on Velicept Therapeut... |
| 03.12.2015 | Velicept nets $21M for overactive bladder drug | Solabegron works by relaxing the bladder smooth muscle by stimulating beta 3-adenoreceptors. Previous Phase 2 work found an improvement of overactive bladder symptoms as compared to placebo. Phase 2 trials for IBS showed improvements in pai... |
| 02.12.2015 | Daily funding roundup - December 2, 2015 | ORIC Pharmaceuticals bagged $53M; Bluecore raised $21M; Osaro announced $3.3M funding
Technology innovators Realsafe Technologies have secured £1 million (approximately $1.5 million) of investment to scale their business, bringing with it n... |
| 01.12.2015 | Velicept Therapeutics Closes First Tranche of $21M Series B Financing | Velicept Therapeutics, Inc., a Malvern, PA-based clinical development company, closed on the first tranche of a $21m Series B financing.
The round was led by CAM Capital and Longitude Capital.
The company intends to use the funds to advance... |
| - | Velicept nets $21M for overactive bladder drug | Pennsylvania startup Velicept Therapeutics has closed out the first tranche of a $21 million Series B financing – meant to advance Phase 2 development of its overactive bladder treatment.
The company plans to test higher doses of its overac... |
